AbRegen is a preclinical stage biotechnology company that specialises in the development of antibody-based
therapeutics for tissue repair applications.
Ferronova is a cancer diagnostics company, developing magnetic probe and tracer systems for improved lymph node identification.
A novel class of 14-3-3 targeting anti-cancer drugs.
A novel biomarker based test for better prognosis of patients with multiple myeloma.
Australian Indigenous native plant bioactive extracts and compounds with potent non-steroidal anti-inflammatory activity.
Off the shelf solution for drug response testing.
Painless, low cost and safe bioactive delivery system.
Dry powder formulation that affords high drug and lipid stability through the micro-encapsulation approach.
Novel formulation approach that direct antibiotics into biofilm (chronic) infections, enhancing the efficacy of cationic antimicrobials by at least 100-fold against biofilm bacterial infections.
In development for treatment of Acute Myeloid Leukaemia (AML) and other Cancers.
A novel hybrid drug delivery formulation that can be used in a wide range of therapeutic applications.
Adaptable surface coating to deter cells from attaching.
A graphical user interface that allows non-experts to filter, search and analyse a patient’s genetic variants in a database.